See ((Thrombopoietin Reveptor Agonists)).
Nonpeptide mimetic eltrombopag and peptibody romiplostim.
Eltombopag and romiplostim have efficacy in short and long-term studies of immune thrombocytopenic purpura.
Thrombopoietin receptors are present in early hematopoietic progenitors, and studies suggest thrombopoietin stimulating agents can stimulate myeloid blasts.